Avalo Therapeutics (AVTX) Invested Capital (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Invested Capital data on file, last reported at $68.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 44.44% year-over-year to $68.3 million; the trailing twelve-month figure through Mar 2026 stood at $68.3 million (down 44.44% YoY), and the FY2025 full-year result was $83.0 million, down 37.74% from the prior year.
• Invested Capital for Q1 2026 stood at $68.3 million, down from $83.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $133.4 million in Q4 2024 and bottomed at -$112.5 million in Q1 2024.
• The 5-year median for Invested Capital is $7.3 million (2023), against an average of $29.1 million.
• Peak annual rise in Invested Capital reached 1726.29% in 2024, while the deepest fall reached 1695.79% in 2024.
• A 5-year view of Invested Capital shows it stood at -$10.9 million in 2022, then soared by 166.92% to $7.3 million in 2023, then surged by 1726.29% to $133.4 million in 2024, then tumbled by 37.74% to $83.0 million in 2025, then dropped by 17.74% to $68.3 million in 2026.
• The last three Invested Capital figures came in at $68.3 million (Q1 2026), $83.0 million (Q4 2025), and $91.5 million (Q3 2025), per Business Quant data.

Peer Comparison